Clinical Data AZ claims another win for Imfinzi in frontline liver cancer PharmaphorumAstraZeneca has built the case for Imfinzi in earlier-stage liver cancer with a second phase 3 trial readout in its EMERALD programme.Clinical DataOncologyRead full story pharminent April 2, 2026 (Last updated: April 2, 2026) Pharmaphorum AstraZeneca has built the case for Imfinzi in earlier-stage liver cancer with a second phase 3 trial readout in its EMERALD programme. Clinical DataOncologyRead full story Post navigation Previous: ACC 2026: Meta-analysis supports CagriSema as superior first-line therapy in obesityNext: Pfizer, BioNTech Halt Large US COVID-19 Vaccine Trial Over Slow Enrollment Related Stories Clinical Data Novartis hit as Lp(a) drug fails cardio outcomes trial pharminent September 7, 2026 Clinical Data Major trial of Roche Alzheimer’s drug kicks off in Europe pharminent September 7, 2026 Clinical Data AbbVie’s T cell engager delivers survival benefit in Phase 3 multiple myeloma study pharminent September 4, 2026